Lung PD-L1
| 22C3 PharmDx | 28-8 PharmDx | SP142 Assay | SP263 Assay | |
|---|---|---|---|---|
| Atezolizumab | - | - | 1L (≥50% TC or ≥10% IC), companion | - |
| Durvalumab | - | - | - | consolidation therapy, companion (≥1% TC) |
| Nivolumab | - | - | - | - |
| Pembrolizumab | 1L (≥50% TPS) & 2L (≥1% TPS) companion | - | - | 1L (≥50% TPS) & 2L (≥1% TPS) companion |
Therapies
Stage III, unresectable NSCLC – consolidation therapy
PD-L1 testing: companion - ≥1% TC
VENTANA PD-L1 (SP263) Assay
- OptiView on a VENTANA BenchMark instrument
- NSCLC interpretation guide
- SP263 kit insert
1st line and 2nd line advanced or metastatic NSCLC
PD-L1 testing: companion
1st line: TPS ≥50%
2nd line: TPS ≥1%
VENTANA PD-L1 (SP263) Assay
- OptiView on a VENTANA BenchMark instrument
- NSCLC interpretation guide
- SP263 kit insert
PD-L1 IHC 22C3 PharmDx
- EnVision FLEX visualisation system on Autostainer Link 48/Omnis
- NSCLC interpretation guide
- 22C3 PharmDx insert (Autostainer Link 48)
- 22C3 PharmDx insert (Omnis)